In this episode of the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.
In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.
In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Tom Fletcher, director of Research and Development at FUJIFILM Irvine Scientific; and Bob Newman, PhD, chief scientific director at FUJIFILM Irvine Scientific, about formulation, specifically with how to prepare culture media for use, single use technologies, and automations to create closed systems in cell/gene therapies.
In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
The trend toward digital transformation in biopharmaceutical manufacturing continues as advanced technologies enter the scene and work their way through to manufacturing operations. With the availability of technologies to take automated biomanufacturing from preclinical to commercial-scale, the industry may start to see a wave of changeovers from manual processes to an automated, digital environment. This episode of the Drug Solutions Podcast will discuss the realities of switching over from manual to digital, and what to expect.
In this episode of the Drug Solutions Podcast, Shawn Liu, the president and CEO of Avirmax, relates his experience in entering the cell and gene therapy manufacturing space and how he began his own startup cell and gene therapy CDMO. SPONSOR: Lonza
Dr. Graziella Piras, senior director of Strategic Marketing at 908 Devices, discusses drug development, specifically about monitoring bioprocess parameters and other important technologies important to moving the process forward, with Pharmaceutical Technology editor Jill Murphy.
Chris Spivey, editorial director, hosts a wide ranging discussion on the COVID-19 pandemic response, future government communications, and healthcare funding for mRNA with experts Dr. Kate Broderick, Chief Innovation Officer, Maravai LifeSciences and Dr. Tom Madden, President & CEO at Acuitas Therapeutics.
In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, talks to David Tisi, technical director at Senopsys LLC, and Reenal Gandhi, global business development director for the Prescription Division of Aptar Pharma. In the first segment of the episode, David chats about some of the key challenges impacting oral dosage forms and the approaches and solutions available that are helping developers overcome these hurdles. After, Reenal details the intricacies of intranasal drug dosage forms, such as the convenience and the growth of this route of administration, challenges of development, and the possibilities of repositioning drug products. SPONSOR: Lonza
In this episode, Sergey Vlasenko from Agilent Diagnostics and Genomics Group chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.
In this episode of the Drug Solutions podcast, Jill Murphy, Editor, talks to Michael Schrader, CEO and co-founder of Vaxess, about the fast pace in production in the pharmaceutical industry, mRNA versus DNA for new vaccines, and the new types of technology used for vaccine administration.
In this episode of the Drug Solutions podcast, Grant Playter, Associate Editor, speaks with Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023. Topics of discussion include key areas of investment, where investment is occurring and why, and how the industry is adjusting to post-COVID regulatory and supply chain changes.
In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, talks to Hanns-Christian Mahler, CEO and board member, and Andrea Allmendinger, chief scientific officer, both at ten23 health about some of the hurdles facing developers and manufacturers of biological therapies. Hanns-Christian and Andrea take a closer look at some of the solutions being used within industry to overcome these challenges and focus on the issue of sustainability within this sphere. Finally, they touch upon some of the other potentially important future trends that will impact biologic drug development and manufacturing.
Following disruption in the bio/pharmaceutical supply chain as a result of the COVID pandemic, the outsourcing industry has learned to adapt and push forward in a climate that is dyamically different. In this Drug Solutions podcast episode, Pharmaceutical Technology® spoke with Gil Roth, president of the Pharma & Biopharma Outsourcing Association (PBOA), and Tara Dougal, content director, Pharma portfolio, Informa Markets, on the current challenges facing the outsourcing industry today as well how contract service providers are tackling sustainability and other big trends in the industry. SPONSOR: Lonza
In this episode of the Drug Solutions podcast, Jill Murphy, Editor, talks to Lon Johnson, VP of Sales and Marketing at Colbert Packaging Corporation, about drug packaging solutions, sustainable options for companies to move towards, EPR laws, and the challenges of transitioning to more renewable packaging options. Sponsor: Colbert Packaging
In this episode of the Drug Solutions podcast, Jill Murphy, Editor, talks to Adam C. Fisher, PhD, director of Science Staff and Immediate Office/Office of Pharmaceutical Quality at the Center for Drug Evaluation and Research/FDA, about point of care, patient manufacturing, and new innovative technologies in the industry.
In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, talks to Rhonda Henry, President of Emmes’ BioPharma Group, and Adam Mendizabal, VP and Director of Emmes’ Cell and Gene Therapy Center, about the role contract research organizations (CROs) play in cell and gene therapy development. Rhonda and Adam will discuss the key factors and solutions driving growth in the CRO market with a particular emphasis on cell and gene therapies entering development pipelines, and will address some of the challenges facing the industry and best practices to ensure these limitations are overcome. SPONSOR: Baxter BioPharma Solutions
In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, catches up with Ana Ladino, Ashland’s Global Director—Regulatory Affairs, about the acceptance of a novel excipient onto CDER’s pilot review program, the next steps involved in progressing an excipient through the review program, and the change in industry’s mindset toward review programs in general.